KUSH PARMAR
CIK 1664281 · Co-CEO · last filed 2026-06-12
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$13.78M
Companies
10
Total Filings
54
Lifetime Open-Market Net
$7.55M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TRDA | Director | 1,093,313 | $6.53 | $7.13M | $2.17M | 10 | 2026-06-12 |
| RLYB | Director | 297,371 | $16.16 | $4.80M | $1.26M | 11 | 2024-05-17 |
| Akouos, Inc. (AKUS) Delisted | Director | 0 | $13.29 | $0 | -$3.46M | 5 | 2022-12-02 |
| Q32 Bio Inc. (FIXX) Delisted | Director | 26,880 | $16.82 | $452.2K | -$37.36M | 13 | 2022-06-17 |
| VOR | Director | 88,332 | $20.01 | $1.77M | $4.94M | 3 | 2022-06-16 |
| 5:01 Acquisition Corp. (FVAM) Delisted | Co-CEO | 365,126 | $10.00 | $3.65M | $0 | 4 | 2020-12-01 |
| APRE | 10%+ Owner | 96,304 | $0.61 | $59.1K | $40.00M | 1 | 2019-10-09 |
| ARVN | Director | 1,775 | $8.26 | $14.7K | $0 | 3 | 2019-09-26 |
| scPharmaceuticals Inc. (SCPH) Delisted | Director | — | $5.67 | — | $0 | 1 | 2018-06-21 |
| BOLD | Director | — | $2.47 | — | $0 | 3 | 2018-06-08 |
Recent Filings · Page 5 of 6
54 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-09-18 | ARVN | Other (J) | +3,475 | $0 | EDGAR |
| 2019-06-10 | Q32 Bio Inc. (FIXX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-05-28 | ARVN | Grant (A) | — | $0 | EDGAR |
| 2019-05-20 | Q32 Bio Inc. (FIXX) Delisted | Sell (S) | −615,000 | -$13.20M | EDGAR |
| 2018-12-12 | Q32 Bio Inc. (FIXX) Delisted | Sell (S) | −15,575 | -$405.0K | EDGAR |
| 2018-11-27 | Q32 Bio Inc. (FIXX) Delisted | Sell (S) | −29,682 | -$594.7K | EDGAR |
| 2018-11-20 | Q32 Bio Inc. (FIXX) Delisted | Sell (S) | −525,900 | -$10.62M | EDGAR |
| 2018-06-21 | scPharmaceuticals Inc. (SCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-08 | BOLD | Grant (A) | — | $0 | EDGAR |
| 2018-04-04 | Q32 Bio Inc. (FIXX) Delisted | Conv (C) | +5,392,037 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.